Replimune and Incyte Enter into Clinical Trial Collaboration

31.07.2023 - Replimune Group, Inc. (NASDAQ:REPL), a clinical stage biotechnology company pioneering the development of a novel portfolio of tumor-directed oncolytic immunotherapies, and Incyte (NASDAQ:INCY), a global biopharmaceutical company, today announced a ... Seite 1

Related Keywords

Lance Leopold , Robert Coffin , Clinical Development Hematology , Group Vice , Chief Research , Development Officer , Incyte , Replimune Group ,